Related Experiment Video
Updated: May 20, 2026
09:49
Decellularized Apple-Derived Scaffolds for Bone Tissue Engineering In Vitro and In Vivo
Published on: February 23, 2024
Bioresorbable scaffolds: current evidence and ongoing clinical trials
Christos V Bourantas1, Yaojun Zhang, Vasim Farooq
1Thoraxcenter, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Current Cardiology Reports
|July 20, 2012
Summary
Bioresorbable scaffolds (BRS) offer a temporary solution for coronary artery disease, providing vessel support and then fully absorbing. This approach aims to reduce long-term complications and restore natural vessel function.
Area of Science:
- Biomaterials Science
- Cardiovascular Medicine
- Medical Devices
Background:
- Metallic stents pose risks of late complications.
- Bioresorbable scaffolds (BRS) offer transient support for coronary arteries.
- Complete absorption of BRS preserves vessel integrity and function.
Purpose of the Study:
- To review advances in bioresorbable scaffold technology.
- To present preclinical and clinical evidence for BRS.
- To provide an overview of ongoing clinical trials evaluating BRS.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of data from ongoing clinical trials.
- Synthesis of current knowledge on BRS development and application.
Main Results:
- BRS provide early vessel patency and acute gain.
- The "decomposition" process leads to complete scaffold absorption.
- Reduced risk of late complications compared to metallic stents.
Conclusions:
- Bioresorbable scaffolds represent a significant advancement in coronary stent technology.
- BRS offer a promising alternative to metallic stents with potential for improved long-term outcomes.
- Further clinical evaluation is ongoing to confirm the effectiveness of BRS.
